Search Results
Nov 11, 2025, 16:50 ET DXCM Stockholders With Large Losses Should Contact Robbins LLP for Information About Leading the Dexcom, Inc. Securities Fraud Class Action
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: Robbins LLP
Nov 11, 2025, 16:05 ET Shoulder Innovations Reports Third Quarter 2025 Financial Results and Increases Full-Year Revenue Guidance
replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditures for such replacements or for new capital expenditure requirements; (iii) Adjusted EBITDA also does not reflect changes in, or cash requirements for, our working capital needs or the potentially dilutive impact of stock-based
More news about: Shoulder Innovations
Nov 11, 2025, 16:05 ET QuickLogic Reports Fiscal Third Quarter 2025 Financial Results
charges related to stock-based compensation and restructuring costs, in calculating non-GAAP (i) income (loss) from operations, (ii) net income (loss), (iii) net income (loss) per share, and (iv) gross margin percentage. The Company provides this non-GAAP information to enable investors to evaluate its operating
More news about: QuickLogic Corporation
Nov 11, 2025, 16:05 ET LightPath Technologies Reports Fiscal 2026 First Quarter Financial Results
growth; (ii) our ability to execute on our growth strategy, including with respect to our ability to move towards fully integrated IR camera systems; (iii) expectations regarding growing supply chain risks and Chinese export restrictions on critical minerals; (iv) customer demand of our products; and (vi)
More news about: LightPath Technologies
Nov 11, 2025, 13:53 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
Disease and Movement Disorders® in Honolulu, Hawaii (5-9 October). At the congress, Lundbeck shared Insights into the design of the phase III MASCOT trial and its use of innovative Bayesian progression modeling methods. On 20 September 2025, Lundbeck and Otsuka
More news about: H. Lundbeck A/S
Nov 11, 2025, 13:38 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
Disease and Movement Disorders® in Honolulu, Hawaii (5-9 October). At the congress, Lundbeck shared Insights into the design of the phase III MASCOT trial and its use of innovative Bayesian progression modeling methods. On 20 September 2025, Lundbeck and Otsuka
More news about: H. Lundbeck A/S
Nov 11, 2025, 11:30 ET Medical Device Outsourcing Market to hit $386.08 Billion by 2033 - Grand View Research, Inc.
II Class III Diagnostic imaging Class I Class II Class III
More news about: Grand View Research, Inc.
Nov 11, 2025, 10:51 ET Falcon Gold Targets Expansion of High-Grade Gold System with New Exploration Permit Application at Central Canada Project, Ontario
regional gold-bearing structure. Phase III Drilling to Build on High-Grade Results The newly submitted permit supports Falcon's Phase III drilling, targeting 1.6 kilometres of strike length along the historic Central
More news about: Falcon Gold Corp.
Nov 11, 2025, 09:18 ET Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
of Salarius' and Decoy's research and development programs; (ii) to pay off certain of Decoy's outstanding promissory notes as required thereby; and (iii) for other general corporate purposes, including working capital, research and development, and capital expenditures. Each pre-funded
More news about: Salarius Pharmaceuticals, Inc.
Nov 11, 2025, 09:00 ET Manulife | CQS Investment Management Announces Close of Third Regulatory Capital Vintage, Raising $1.1 Billion
/PRNewswire/ - Manulife | CQS Investment Management (MCQS) today announced the close of its Regulatory Capital Vintage III, raising a total of $1.1 billion across Manulife CQS Regulatory Capital Relief III Fund and separately managed accounts. This fundraising underscores MCQS's experience in the regulatory capital
More news about: Manulife Wealth & Asset Management
Nov 11, 2025, 09:00 ET Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
advancing patient-centric innovation. Study Overview A Phase III, multicenter, randomized, double-blind, non-inferiority trial was conducted across multiple oncology centers in India to compare OERIS™ with
More news about: Shilpa Medicare Limited
Nov 11, 2025, 08:45 ET Investors who lost money on Fluor Corporation(FLR) should contact Levi & Korsinsky about pending Class Action - FLR
hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iii) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was
More news about: Levi & Korsinsky, LLP
Nov 11, 2025, 08:45 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit - DXCM
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: Levi & Korsinsky, LLP
Nov 11, 2025, 08:25 ET Repairon Announces Positive Clinical Outcomes of Engineered Heart Muscle as Reparative Therapy for Advanced Heart Failure Reported at the Scientific Sessions of the American Heart Association
early evidence "We are highly encouraged by what we have seen thus far and look forward to the transitioning of BioVAT-HF Phase II into a pivotal Phase III trial" High medical need in advanced heart failure: Approximately
More news about: Repairon GmbH
Nov 11, 2025, 06:00 ET Hyperscale Data Bitcoin Treasury Rises to $75.25 Million
Hyperscale Data's disciplined capital allocation strategy and our conviction in Bitcoin as a long-term store of value," said Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "While the short-term price of Bitcoin has been volatile, our focus remains on building a resilient
More news about: Hyperscale Data Inc.
Nov 11, 2025, 06:00 ET Gogoro Releases Third Quarter 2025 Financial Results
costs at overseas entities, primarily reflecting the benefits realized from the organizational restructuring implemented in the fourth quarter of 2024, (iii) a $1.4 million reduction in inventory write-downs resulting from more effective inventory management and optimization, and (iv) lower depreciation across
More news about: Gogoro
Nov 11, 2025, 04:00 ET Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
advancing patient-centric innovation. Study Overview A Phase III, multicenter, randomized, double-blind, non-inferiority trial was conducted across multiple oncology centers in India to compare OERIS™ with
More news about: Shilpa Medicare Limited
Nov 11, 2025, 03:00 ET Shilpa Medicare annonce des résultats positifs de la phase 3 pour OERIS™ - une nouvelle injection d'ondansétron à libération prolongée une fois par semaine pour les nausées et vomissements induits par la chimiothérapie (NVIC)
patient. Aperçu de l'étude Un essai de non-infériorité de Phase III, multicentrique, randomisé, en double aveugle a été effectué dans plusieurs centres d'oncologie en Inde pour comparer OERIS™ à des injections
More news about: Shilpa Medicare Limited
Nov 11, 2025, 02:34 ET Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
including China, the European Union, the United Kingdom, Singapore, and India, benefiting more than 110,000 patients worldwide. On 9 October, the Phase III clinical trial of HANSIZHUANG for perioperative gastric cancer met its primary endpoint, supporting an early drug application for market approval and
More news about: Fosun
Nov 10, 2025, 20:09 ET DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
https://investor.pacira.com/static-files/c8ab0563-7208-40ce-912f-9be1a41c585bii Bloomberg Database, DOMA Perpetual Internal Calculationsiii Pacira BioSciences, Inc. Company Filingsiv Pacira BioSciences, Inc. (2025, May 8). Pacira BioSciences reports first quarter
More news about: DOMA Perpetual
Nov 10, 2025, 17:31 ET Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms | DelveInsight
from an ongoing Phase II/III study evaluating BNT113 in combination with PD-1 blockade and results from an investigator-initiated Phase I/II trial testing BNT113 as monotherapy in HPV16-driven cancers. Currently, BNT113 is being assessed in a Phase II/III clinical trial comparing
More news about: DelveInsight Business Research, LLP
Nov 10, 2025, 17:30 ET TEN Holdings Reports Third Quarter 2025 Financial Results
the foundational groundwork for future revenue growth and operational efficiency," said TEN Holdings Chief Executive Officer, Randolph Wilson Jones III. "The quarter also saw us announce two pivotal achievements, the first of which was the launch of an Early Adopter Program for
More news about: TEN Holdings, Inc.
Nov 10, 2025, 16:40 ET Miami International Holdings Announces Expanded Roles for Shelly Brown and Joseph W. Ferraro
building and operating regulated financial markets across multiple asset classes, today announced expanded roles for Shelly Brown and Joseph W. Ferraro III—key members of its senior management team—to support strategic growth initiatives at MIAX Futures™. These appointments are effective today.
More news about: MIAX
Nov 10, 2025, 16:40 ET Miami International Holdings Announces Expanded Roles for Shelly Brown and Joseph W. Ferraro
building and operating regulated financial markets across multiple asset classes, today announced expanded roles for Shelly Brown and Joseph W. Ferraro III—key members of its senior management team—to support strategic growth initiatives at MIAX Futures™. These appointments are effective today.
More news about: MIAX
Nov 10, 2025, 16:30 ET LivePerson Announces Third Quarter 2025 Financial Results
divestiture, IT transformation costs, acquisition and divestiture costs, loss on divestiture, and other expense (income), net, divided by revenue; (iii) adjusted operating (loss) income, or net income (loss) before provision for income taxes, interest expense, interest income, amortization of purchased
More news about: LivePerson